Contrasting Interpace Biosciences (OTCMKTS:IDXG) and Ramsay Health Care (OTCMKTS:RMSYF)

Ramsay Health Care (OTCMKTS:RMSYF) and Interpace Biosciences (OTCMKTS:IDXG) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Ramsay Health Care and Interpace Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ramsay Health Care	0	0	1	0	3.00
Interpace Biosciences	0	0	0	0	0.00

Ramsay Health Care presently has a consensus target price of $54.10, indicating a potential upside of 47.75%. Given Ramsay Health Care’s stronger consensus rating and higher probable upside, equities analysts plainly believe Ramsay Health Care is more favorable than Interpace Biosciences.

Earnings & Valuation

This table compares Ramsay Health Care and Interpace Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ramsay Health Care	N/A	N/A	N/A	$1.43	25.60
Interpace Biosciences	$38.73 million	0.17	$24.58 million	$0.08	18.12

Interpace Biosciences has higher revenue and earnings than Ramsay Health Care. Interpace Biosciences is trading at a lower price-to-earnings ratio than Ramsay Health Care, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ramsay Health Care and Interpace Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ramsay Health Care	N/A	N/A	N/A
Interpace Biosciences	67.64%	145.40%	87.36%

Insider and Institutional Ownership

13.2% of Ramsay Health Care shares are held by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are held by institutional investors. 0.9% of Interpace Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Ramsay Health Care beats Interpace Biosciences on 6 of the 11 factors compared between the two stocks.

About Ramsay Health Care

Ramsay Health Care Limited owns and operates hospitals. The company offers health care services to public and private patients. It operates facilities in approximately 530 locations in the Asia Pacific, the United Kingdom, France, and Nordics. Ramsay Health Care Limited was founded in 1964 and is based in Sydney, Australia.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.